MHRA, BARDA, European Commission and Big Pharma Gather Next Month at 18th Annual Superbugs & Superdrugs Summit: Attendee List Released

London, United Kingdom, February 17, 2016 --(PR.com)-- The popularity of the event highlights the imminent global threat of antimicrobial resistance and the urgency for scientists and drug developers to discover new alternatives to bacteria resistant treatments. With 50 participants already registered and with still over a month to go until doors open, early indications predict that the event is set to sell out when it returns to London this spring.

The agenda will feature 20 thought-provoking presentations from leading pharmaceutical organisations and industry experts; spotlight sessions on industry incentive and partnerships; progressive insight into drug discovery; best practices in antimicrobial stewardship; and topical panel debates to both new and seasoned stakeholders.

In a statement made by the conference chairing committee, the importance of industry collaboration was emphasised by co-chairs, Richard Bax, Senior Partner from Transcrip Partners; and Lloyd Czaplewski, Director of Chemical Biology Ventures.

“Antimicrobial resistance is clearly a serious global threat. To combat potential epidemic, requires both industry and government collaboration on an international level in antibiotics R&D investments, preventive measures and emergency response…To curb an uncontrollable outbreak ‘storm,’ we urge committed action and international stewardship from the industry to drive anti-superbugs and superdrug developments.”

The US Government Federal Agency, BARDA, who will be making a keynote address said:

“In the the U.S. alone, antimicrobial resistant bacterial pathogens are responsible for 2M infections and 23,000 deaths annually with an estimated annual economic burden of $35B…. In the near future, routine medical procedures and operations that we currently take for granted may become too risky due to the high risk of death from drug-resistant bacterial infections. This is the result of the pace of antibacterial drug development not keeping pace with the rate of resistance development.” – Head of Anti-Infectives Program Division of CBRN Countermeasures, BARDA

Those who have confirmed attendance include:
ACT Surfaces, Arsanis Biosciences, Auspherix, BARDA, Blueberry Therapeutics, Cantab Anti-infectives, Cempra Pharmaceuticals, Chemical Biology Ventures, Drugs for Neglected Diseases initiative (DNDi), Emergent BioSolutions, European Commision, Evotec, F. Hoffmann-La Roche, MGB Biopharma, MHRA, Mutabilis, Neem Biotech, Nemesis bioscience, NeoSome Life Sciences, Northern Antibiotics, Nosopharm, Phico Therapeutics, Public Health England, QuantumDX, Spero Therapeutics, Tiber Creek Partners, TNO Pharma, TranScrip Partners and more…

Both a full preliminary list off attendees and the interview with BARDA, is available to download online in the event “download center” at http://www.superbugssuperdrugs.com/prcom.

For further information, visit: http://www.superbugssuperdrugs.com/prcom

SMi’s 18th annual conference:
Superbugs & Superdrugs
16th & 17th March 2016
Holiday Inn Kensington Forum, London UK

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk